ReviewInternational journal of general medicine2025
Beyond the Skin: Exploring the Gut-Skin Axis and Metabolic Pathways in Atopic Dermatitis Pathogenesis.
Review in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Shotgun Metagenomic Characterization of Skin Microbiome Shifts in Human Scabies Before and After Scabicidal Treatment.International journal of molecular sciences · 2026Article
- The Gut-Skin Axis in Atopic Dermatitis and Inflammatory Bowel Disease: Mechanisms, Microbiota, and Therapeutic Implications.Journal of personalized medicine · 2026Review
- Oral PHGG ameliorates atopic dermatitis-like dermatitis with concurrent modulation of colonic IgA and cecal microbiota: implications for the gut-skin axis.Journal of the science of food and agriculture · 2026Article
- Atopic Dermatitis Beyond Cutaneous Inflammation: The Interplay Between Progesterone, Testosterone, Gut Microbiota, and Immune Dysregulation.Microorganisms · 2026Review
- Tryptophan Metabolism at the Crossroads of Immunity, Barrier Function, and the Microbiome in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2026Review
- Preliminary Characterization of Skin Microbiota and Mycobiota in Atopic Dermatitis by Metagenomic and Culture-Based Analyses.Life (Basel, Switzerland) · 2026Article
- Review
- Gut-Brain Inflammation and Disrupted Homeostasis Due to Activation of Mast Cells and Microglia.International journal of molecular sciences · 2026Review
- The Collaborative Collapse: Bile Acid Dysmetabolism as a Central Pathogenic Driver in Canine and Feline Multi-Systemic Disorders-From Mechanisms to Precision Therapeutics.Veterinary sciences · 2026Review
- An online program focusing on modifiable lifestyle and environmental interventions was associated with improved pediatric eczema symptoms: results from a retrospective observational study.Frontiers in allergy · 2026Article
- Screening of Metabolic Reprogramming-Related Diagnostic Biomarkers and Analysis of Immune Heterogeneity in Atopic Dermatitis Based on Multi-Cohort Validation.Clinical, cosmetic and investigational dermatology · 2026Article
- Engineering Multi-Scale Transdermal Delivery Systems for Atopic Dermatitis: Emerging Insights from the Gut-Skin Axis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD), is a chronic, recurrent inflammatory skin condition characterized by eczema-like lesions, itching, and dryness. It often coexists with other atopic comorbidities, including food allergies (FA), allergic rhinitis (AR), and allergic asthma (AA). The pathogenesis of AD is complex and multifactorial, involving immune dysregulation, epidermal barrier disruption, and dysbiosis of intestinal and skin microbiota. Recent research has increasingly focused on the gut-skin axis, highlighting the role of intestinal microbiota and their metabolic products in regulating skin immunity and barrier function. Dietary changes and metabolic pathway modulation are emerging as promising therapeutic strategies. This article reviews recent advancements in AD research across three dimensions: gut microbiota, metabolomics, and comorbidities, while exploring potential therapeutic approaches to regulate gut microbiota and target metabolic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.